Mefloquine-sulfadoxine-pyrimethamine (MSP) is a fixed-dose combination antimalarial drug that combines the actions of mefloquine, sulfadoxine, and pyrimethamine. Mefloquine is a quinoline antimalarial that acts as a blood schizonticide, inhibiting the growth of the parasite within red blood cells. Sulfadoxine and pyrimethamine are antifolates that inhibit the parasite's dihydrofolate reductase (DHFR) enzyme, which is essential for DNA synthesis. The combination of these three drugs is highly effective against Plasmodium falciparum, the most deadly form of malaria. MSP is particularly useful in areas where resistance to other antimalarial drugs is high. The combination of the drugs in MSP allows for a more effective treatment regimen, and the slower elimination of mefloquine from the body provides prolonged protection against malaria. MSP is a highly effective treatment for uncomplicated malaria, but it is not recommended for pregnant women or breastfeeding mothers. Some studies have shown that MSP may be associated with an increased risk of seizures, but this is uncommon. MSP is a valuable tool in the fight against malaria, and it is important to use it according to the guidelines to ensure its effectiveness and safety.'
```
mefloquine-sulfadoxine-pyrimethamine: combination of mefloquine, sulfadoxine, pyrimethamine [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 114972 |
| MeSH ID | M0135549 |
| Synonym |
|---|
| mefloquine hydrochloride combination with sulfadoxine and pyrimethamine |
| msp 4 |
| mefloquine-sulfadoxine-pyrimethamine |
| benzenesulfonamide, 4-amino-n-(5,6-dimethoxy-4-pyrimidinyl)-, mixt. with 5-(4-chlorophenyl)-6-ethyl-2,4-pyrimidinediamine and (r*,s*)-(+-)-alpha-2-piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol monohydrochloride |
| fansimef |
| 69191-18-0 |
| fansimef r |
| 4-amino-n-(5,6-dimethoxypyrimidin-4-yl)benzenesulfonamide;(s)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2r)-piperidin-2-yl]methanol;5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine;hydrochloride |
| hqwqvbjuiijtre-lkrnktnvsa-n |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Toxic encephalopathy is a serious neurological manifestation which is slowly reversible depending on individual predisposition." | ( [Danger of malaria self-treatment. Acute neurologic toxicity of mefloquine and its combination with pyrimethamine-sulfadoxine]. Granier, H; Laborde, JP; Martin, J; Nicolas, X; Talarmin, F, 2001) | 0.31 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Several assay methodologies have been developed, but high performance liquid chromatography has been the most used in recent pharmacokinetic studies." | ( Clinical pharmacokinetics of mefloquine. Karbwang, J; White, NJ, 1990) | 0.28 |
| " The pharmacokinetic evaluation of each of the three components was based on the assumption of an open linear two-compartment model." | ( Multiple-dose pharmacokinetics of the antimalarial drug Fansimef (pyrimethamine + sulfadoxine + mefloquine) in healthy subjects. Heizmann, P; Mimica, I; Portmann, R; Schwartz, DE; Weidekamm, E, 1987) | 0.27 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " 175 Europeans travelling to different malaria endemic areas received either mefloquine alone (250 mg/week) or its combination with sulfadoxine (500 mg/week) plus pyrimethamine (25 mg/week)." | ( Tolerance of mefloquine alone and in combination with sulfadoxine-pyrimethamine in the prophylaxis of malaria. Dietrich, M; Horstmann, RD; Reisinger, EC, ) | 0.13 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " The dosage of mefloquine is 250 mg weekly (1 tablet Lariam) for 4 weeks, followed by 1 tablet every fortnight." | ( [Malaria in Switzerland]. Fernex, M, 1988) | 0.27 |
| " Six Brazilian volunteers received a loading dose of 2 tablets followed by 20 maintenance doses of 1 tablet at a dosage interval of 7 days." | ( Multiple-dose pharmacokinetics of the antimalarial drug Fansimef (pyrimethamine + sulfadoxine + mefloquine) in healthy subjects. Heizmann, P; Mimica, I; Portmann, R; Schwartz, DE; Weidekamm, E, 1987) | 0.27 |
| "We report the case of a patient who did not follow the prescribed dosage and who developed acute neurological disorders after overdosing." | ( [Danger of malaria self-treatment. Acute neurologic toxicity of mefloquine and its combination with pyrimethamine-sulfadoxine]. Granier, H; Laborde, JP; Martin, J; Nicolas, X; Talarmin, F, 2001) | 0.31 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 18 (46.15) | 18.7374 |
| 1990's | 19 (48.72) | 18.2507 |
| 2000's | 2 (5.13) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (10.02) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 20 (46.51%) | 5.53% |
| Reviews | 3 (6.98%) | 6.00% |
| Case Studies | 1 (2.33%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 19 (44.19%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||